期刊文献+

HPLC-CAD法测定伐地那非原料药的含量及有关物质 被引量:5

Determination of the Content and Related Substances of Vardenafil by HPLC-CAD
下载PDF
导出
摘要 目的:建立HPLC-CAD法测定伐地那非原料药的含量及有关物质。方法:采用Agilent ZORBAX Eclipse XDB C18色谱柱(250 mm×4. 6 mm,5μm),流动相:0. 01 mol·L^(-1)乙酸铵(乙酸调p H至6. 0)-乙腈,流速:1. 0 ml·min^(-1),柱温:35℃,CAD雾化器温度:35℃,进样量:20μl。结果:伐地那非主成分与各有关物质均能有效地分离,伐地那非的进样量在0. 408~10. 200μg内与峰面积呈良好的线性关系(r=0. 999 4),平均回收率为99. 2%(RSD=1. 5%,n=9);单个杂质限量定为0. 1%,杂质总量为0. 5%。结论:本法准确,简便,灵敏度高,可用于伐地那非原料药的含量测定以及有关物质检测。 Objective: To establish an HPLC-CAD method for the determination of vardenafil and its related substances. Methods:An Agilent ZORBAX Eclipse XDB C18 column(250 mm × 4. 60 mm,5 μm) was used,the mobile phase consisted of 0. 02 mol·L-1 ammonium acetate solution( adjusting p H to 6. 0 with acetic acid)-acetonitrile,the flow rate was 1. 0 ml·min-1,the column temperature was 35℃,the nebulization temperature of detector was 35 ℃,and the injection volume was 20 μl. Results: Vardenafil and all the related compounds could be well separated. The linear range of vardenafil was 0. 408-10. 200 μg( r = 0. 999 4),and the average recovery was 99. 2%( RSD = 1. 5%,n = 9). The single impurity limit was set at 0. 1% and the limit of total impurities was set at0. 5%. Conclusion: The method is accurate,convenient and sensitive,and can be applied in the determination of the content and related substances of vardenafil.
作者 吴川彦 罗霞 Wu Chuanan;Luo Xia(Chengdu Food and Drug Inspection Institute,Chengdu 610041,China)
出处 《中国药师》 CAS 2018年第12期2251-2254,共4页 China Pharmacist
关键词 伐地那非 高效液相色谱法 含量测定 有关物质 Vardenafil HPLC-CAD Determination Related substance
  • 相关文献

参考文献5

二级参考文献81

  • 1朱积川,姜辉.伐地那非治疗勃起功能障碍的有效性和安全性[J].中华男科学杂志,2004,10(9):704-710. 被引量:10
  • 2金杰,贺占举,张凯,朱积川,姜辉,潘天明,庄申镕,洪铠,唐文豪,马洪铭,王晓雄,何学酉,宋涛,黄翼然,周立新,戴继灿,丁强,方杰,徐罡,蔡松良,陈军,金晓东,郭应禄.伐地那非治疗勃起功能障碍的多中心、随机、双盲、对照研究[J].中华泌尿外科杂志,2005,26(1):54-58. 被引量:5
  • 3邓春华,孙祥宙.应用新的治疗满意度量表来评估ED患者及其性伴侣对伐地那非治疗的满意度[J].中华男科学杂志,2005,11(9):716-719. 被引量:4
  • 4周少虎,谢建兴,陈铭,王强,陈吉文.女性伴侣在勃起功能障碍的诊治中的重要地位[J].中华男科学杂志,2006,12(5):473-476. 被引量:2
  • 5Montorsi F, Padma-Nathan H, Buvat J, et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: A randomized, double-blind placebo-controlled triM. J Sex Med, 2004, 1(2) : 168-178.
  • 6Valiquette L, Montorsi F, Hellstrom WJ, et al. Penetration and maintenance of erection with vardenafil: A time-from-dosing analysis. Can J Urol, 2005, 12(3) : 2687-2698; discussion 2699.
  • 7Ahhof SE. Quality of life and erectile dysfunction. Urology, 2002, 59(6) : 803-810.
  • 8Fisher WA, Rosen RC, Eardley I, et al. Sexual experience of female partners of men with erectile dysfunction: The female experience of men's attitudes to life events and sexuality(FEMALES) study. J Sex Med, 2005, 2(5) : 675-684.
  • 9Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors : The day after. Eur Urol, 2007,51 ( 1 ) : 75-88 ; discussion 89.
  • 10Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res, 2001,13 (5) : 282-290.

共引文献67

同被引文献68

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部